Showing 171-180 of 7665 results for "".
- Mediterranean Diet Adherence Not a Factor in Diagnosis or Severity of Acne: Studyhttps://practicaldermatology.com/news/mediterranian-diet-not-linked-with-acne-development-study/2462437/Results from a new analysis in the Journal of Health, Population, and Nutrition failed to show a link between adherence to a Mediterranean diet and an impact on acne severity or diagnosis. "Western diets, characterized by a high glycemic index and dairy content, can be risk factors for acne vulgar…
- Analysis of Dermatology Mobile Apps with AI Capability Reveals Weaknesses, Transparency Concernshttps://practicaldermatology.com/news/analysis-of-dermatology-mobile-apps-reveals-weaknesses-transparency-concerns/2462434/A new analysis of dermatology mobile applications (apps) revealed transparency, validation, and accuracy concerns. "With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applications (app…
- LEO Pharma Presents New Long-Term Adbry (Tralokinumab-ldrm) Data in Adults with Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharma-presents-new-long-term-adbry-tralokinumab-ldrm-data-in-adults-with-moderate-to-severe-ad/2462432/LEO Pharma unveiled new data analyzing the long-term therapeutic response of treatment with Adbry (tralokinumab-ldrm) in adults with moderate-to-severe atopic dermatitis (AD). The findings were shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego.[1] “The …
- Study: Seborrheic Dermatitis Has Distinct Molecular Signaturehttps://practicaldermatology.com/news/study-seborrheic-dermatitis-has-distinct-molecular-signature/2462428/Newly unveiled research suggests that seborrheic dermatitis has its own unique molecular signature and is distinct in its own disease-specific pattern. “The pathophysiology of seborrheic dermatitis has been poorly understood. We sought to understand the gene expression patterns in seborrheic dermat…
- FRONTIER-2: Novel Oral Peptide Maintains Safety, Efficacy Out to 1 Yearhttps://practicaldermatology.com/news/frontier-2-novel-il-23-targting-oral-peptide-maintains-safety-efficacy-out-to-1-year/2462424/A targeted oral peptide targeting interleukin-23 (IL-23) was associated with high rates of clearance and consistent safety through 1 year of treatment in adults with moderate-to-severe plaque psoriasis, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in Sa…
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis. Alumis pl…
- Pediatric Atopic Dermatitis Associated with Learning, Memory Difficultieshttps://practicaldermatology.com/news/symptoms-of-cognitive-impairment-among-children-with-atopic-dermatitis/2462263/New research links pediatric atopic dermatitis (AD) with higher odds of memory and learning difficulties. "Previous studies suggest that atopic dermatitis (AD) is associated with cognitive impairment in children, but these studies have relied primarily on neurodevelopmental diagnoses (rather than …
- Bimekizumab Not Linked with Depression, Suicidal Ideation in Moderate-to-Severe Psoriasishttps://practicaldermatology.com/news/mental-health-outcomes-in-patients-with-moderate-to-severe-psoriasis-treated-with-bimekizumab-analysis-of-phase-23-randomized-trials/2462260/A new analysis indicates that bimekizumab was not associated with a high risk of suicidal ideation/behavior (SIB) and depression. Psoriasis patients often face increased risks of SIB and depression, according to the researchers. Bimekizumab, an FDA-approved biologic inhibiting interleukin (IL)-17A…
- Galderma to Showcase Latest Updates From Its Dermatology Portfolio at the 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/galderma-to-showcase-latest-updates-from-its-dermatology-portfolio-at-the-2024-american-academy-of-dermatology-annual-meeting-1/2462259/Galderma will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) annual meeting from March 8-12, 2024, highlighting its dermatology portfolio. Galderma’s presence includes two late-breaking presentations on its first-in-class, investigational mono…
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous melanoma…